Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKT cell infusion in advanced solid tumors
NCT02562963Phase 2Unknown
- Start
- Nov 2015
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial in non-small cell lung cancer (NSCLC), gastric cancer (GC), hepatocellular carcinoma (HCC) and 1 more. Primary endpoint: Incidence of adverse events at 30 days. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)gastric cancer (GC)hepatocellular carcinoma (HCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02562963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562963.